The global Plant-based Vaccines Market is estimated to be valued at US$ 43.7 Mn in 2021 and is expected to exhibit a CAGR of 49.9% over the forecast period 2023-2030, as highlighted in a new report published by Coherent Market Insights.

Market Overview:
Plant-based vaccines are derived from plants through genetic engineering techniques. These vaccines offer numerous advantages such as cost-effectiveness, scalability, and production sustainability. The need for plant-based vaccines is driven by the increasing demand for effective and affordable vaccines, especially in developing countries. Additionally, plant-based production platforms provide opportunities for rapid vaccine development and production, which is crucial in response to emerging infectious diseases.

Market Key Trends:
One key trend in the Plant-based Vaccines Market is the growing adoption of plant-based vaccine production for pandemic preparedness. The recent COVID-19 pandemic has highlighted the need for rapid vaccine development and production. Plant-based platforms offer advantages in terms of scalability and rapid response compared to traditional vaccine production methods. The ability to quickly modify plant production systems and adapt them to produce different antigens makes plant-based vaccines a promising solution in pandemic situations.

Overall, the Plant-based Vaccines Market is witnessing significant growth due to the increasing need for sustainable and scalable vaccine production. The adoption of plant-based platforms for pandemic preparedness is expected to drive the market in the coming years.
Porter’s Analysis

Threat of new entrants:

The threat of new entrants in the plant-based vaccines market is relatively low due to the high barriers to entry. Developing and producing plant-based vaccines requires specialized knowledge, expertise, and significant investments in research and development. Additionally, obtaining regulatory approvals and establishing manufacturing facilities can be time-consuming and costly. As a result, existing players have a competitive advantage and it is difficult for new entrants to enter the market.

Bargaining power of buyers:

Buyers in the plant-based vaccines market have moderate bargaining power. While there are a limited number of suppliers in the market, customers have the option to choose from various types of vaccines. This gives them some leverage in negotiating prices and terms with the suppliers. However, the critical nature of vaccines and the lack of substitute products limit the extent to which buyers can exert pressure on suppliers.

Bargaining power of suppliers:

Suppliers in the plant-based vaccines market have relatively high bargaining power. There are a limited number of companies that specialize in plant-based vaccine production, giving them a significant advantage. Suppliers can demand higher prices and negotiate favorable terms due to the specialized nature of their products and the high demand for vaccines. Additionally, suppliers have the ability to switch to other buyers if they feel that their requirements are not being met.

Threat of new substitutes:

The threat of new substitutes in the plant-based vaccines market is low. Vaccines are essential for preventing diseases and there are limited alternatives available. Traditional vaccines, such as those made from animal or microbial sources, have been widely used for decades. However, the development and adoption of plant-based vaccines offer unique advantages, such as scalability, safety, and cost-effectiveness. These factors reduce the likelihood of substitution by other forms of vaccines.

Competitive rivalry:

The competitive rivalry in the plant-based vaccines market is high. The market is dominated by a few key players who have established a strong presence and hold a significant market share. These companies compete on factors such as product efficacy, safety, regulatory compliance, production capacity, and pricing. The high growth potential of the market has attracted new entrants, intensifying the competition further.

Key Takeaways

The Global Plant-Based Vaccines Market Demand is expected to witness high growth, exhibiting a CAGR of 49.9% over the forecast period (2023-2030). This growth is driven by increasing investments in research and development for plant-based vaccine production, growing prevalence of infectious diseases, and the need for more cost-effective and scalable vaccine production methods.

In terms of regional analysis, North America is the fastest-growing and dominating region in the plant-based vaccines market. The region has a well-developed healthcare infrastructure, strong government support for research and development, and a high prevalence of infectious diseases. Additionally, the presence of key players in the region further contributes to its dominance.

Key players operating in the plant-based vaccines market include Medicago, Inc., IBIO, Inc., Icon Genetics GmbH, Lumen Bioscience, Inc., British American Tobacco Plc., Creative Biolabs, Inc., Leaf Expression Systems Ltd., ZYUS Life Sciences Inc., PlantForm Corporation, and Infectious Disease Research Institute (IDRI). These companies have a significant market presence and are actively involved in research, development, and commercialization of plant-based vaccines.

Overall, the plant-based vaccines market is poised for significant growth due to increasing demand, technological advancements, and favorable government initiatives. The market offers immense opportunities for both existing players and new entrants, with a focus on improving vaccine production, efficacy, and affordability.